Compare BFST & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFST | MNKD |
|---|---|---|
| Founded | 2006 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.1M | 793.6M |
| IPO Year | 2014 | 2004 |
| Metric | BFST | MNKD |
|---|---|---|
| Price | $28.39 | $2.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $32.75 | $8.56 |
| AVG Volume (30 Days) | 148.8K | ★ 3.8M |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 23.45 | N/A |
| EPS | ★ 2.79 | 0.02 |
| Revenue | $10,704,000.00 | ★ $348,966,000.00 |
| Revenue This Year | $22.71 | $35.81 |
| Revenue Next Year | $5.02 | $11.89 |
| P/E Ratio | ★ $10.09 | $136.25 |
| Revenue Growth | 1.20 | ★ 22.23 |
| 52 Week Low | $22.25 | $2.23 |
| 52 Week High | $30.32 | $6.51 |
| Indicator | BFST | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 56.88 | 44.63 |
| Support Level | $25.68 | $2.52 |
| Resistance Level | $28.74 | $6.18 |
| Average True Range (ATR) | 0.66 | 0.12 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 61.75 | 49.11 |
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.